|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...102103104105106107108109110111112...156157» |
- | Avonex (recombinant IFN-β-1a) / Biogen
New P4 trial, HEOR: SFERA: Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen (clinicaltrials.gov) - Mar 2, 2014
P4, N=50, Recruiting, Sponsor: Biogen Idec
- | ATX-MS-1467 / Apitope
Enrollment open: ATX-MS-1467 in Multiple Sclerosis (clinicaltrials.gov) - Mar 2, 2014
P2, N=20, Recruiting, Sponsor: Merck KGaA
Not yet recruiting --> Recruiting
- ||| Smyraf (peficitinib) / Astellas, Maruho
Enrollment closed, P2 data: A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study (clinicaltrials.gov) - Mar 2, 2014
P2, N=611, Active, not recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- mycophenolate mofetil / Generic mfg.
Enrollment closed: Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis (clinicaltrials.gov) - Mar 2, 2014
P4, N=100, Active, not recruiting, Sponsor: Tuen Mun Hospital
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- mycophenolate mofetil / Generic mfg.
Trial completion: Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis (clinicaltrials.gov) - Mar 2, 2014
P4, N=20, Completed, Sponsor: Tuen Mun Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| Orencia (abatacept) / BMS
Trial completion: Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Mar 2, 2014
P1/2, N=87, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Lusduna (insulin glargine biosimilar) / Samsung
Enrollment open: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005) (clinicaltrials.gov) - Mar 2, 2014
P1, N=130, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Combination therapy, Monotherapy: A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate (clinicaltrials.gov) - Mar 2, 2014
P3, N=77, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Mar 2, 2014
P3, N=41, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Completed
- | gevokizumab (VPM087) / Novartis
Trial completion: Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes (clinicaltrials.gov) - Mar 2, 2014
P2, N=22, Completed, Sponsor: XOMA (US) LLC
Recruiting --> Completed Active, not recruiting --> Completed
- | Dekavil (F8-IL10) / Pfizer
New P1 trial, Combination therapy: Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Feb 28, 2014
P1, N=34, Recruiting, Sponsor: Philogen S.p.A.
- |||||||||| Tavalisse (fostamatinib) / Rigel
New P3 trial: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Feb 27, 2014
P3, N=75, Not yet recruiting, Sponsor: Rigel Pharmaceuticals
- |||||||||| Tavalisse (fostamatinib) / Rigel
New P3 trial: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Feb 27, 2014
P3, N=75, Not yet recruiting, Sponsor: Rigel Pharmaceuticals
- |||||| Lantus (insulin glargine) / Sanofi, Lusduna (insulin glargine biosimilar) / Samsung
Enrollment open: A Study of the Safety and Efficacy of MK-1293 Compared to Lantus (clinicaltrials.gov) - Feb 27, 2014
P3, N=500, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Benlysta (belimumab) / GSK
Enrollment change, IO biomarker: A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy (clinicaltrials.gov) - Feb 26, 2014
P2, N=18, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=12 --> 18
- ||||| Remaloce (infliximab biosimilar) / Yuhan Corp, Biogen, Ewopharma, Merck (MSD), Samsung
Enrollment closed: A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - Feb 26, 2014
P3, N=584, Active, not recruiting, Sponsor: Samsung Bioepis Co., Ltd.
N=12 --> 18 Recruiting --> Active, not recruiting
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial initiation date: Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate (clinicaltrials.gov) - Feb 26, 2014
P4, N=120, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Initiation date: Jun 2013 --> Sep 2013
- |||||||||| blisibimod (A-623) / Anthera Pharma
New P3 trial: CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis (clinicaltrials.gov) - Feb 26, 2014
P3, N=400, Not yet recruiting, Sponsor: Anthera Pharmaceuticals
- |||| Enrollment open: BiobankII: Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis (clinicaltrials.gov) - Feb 26, 2014
P4, N=250, Recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
Initiation date: Jun 2013 --> Sep 2013 Not yet recruiting --> Recruiting
- Fumaderm (dimethyl fumarate) / Biogen
Trial completion: FumaCLE: Efficacy and Safety of Fumaric Acid Esters (Fumaderm (clinicaltrials.gov) - Feb 26, 2014
P2, N=11, Completed, Sponsor: University Hospital Muenster
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: Study of PTPN22 C1858T Polymorphism in Children and Adolescents of Greek Origin With T1DM (clinicaltrials.gov) - Feb 26, 2014
P=N/A, N=200, Completed, Sponsor: Aristotle University Of Thessaloniki
Active, not recruiting --> Completed Recruiting --> Completed
- Trial initiation date: Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS) (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=34, Not yet recruiting, Sponsor: Hadassah Medical Organization
Recruiting --> Completed Initiation date: Jun 2013 --> Feb 2014
- Enrollment change: Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS) (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=34, Not yet recruiting, Sponsor: Hadassah Medical Organization
Initiation date: Jun 2013 --> Feb 2014 N=130 --> 34
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Combination therapy: A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Feb 25, 2014
P3, N=1196, Completed, Sponsor: Hoffmann-La Roche
N=130 --> 34 Active, not recruiting --> Completed
- Cimzia (certolizumab pegol) / Astellas, UCB
Biomarker, Enrollment change, IO biomarker, Immunomodulating, Biopsy: Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia) (clinicaltrials.gov) - Feb 25, 2014
P3, N=12, Completed, Sponsor: Nathan Wei, MD, FACP, FACR:
Active, not recruiting --> Completed N=10 --> 12
- H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Enrollment open: Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies. (clinicaltrials.gov) - Feb 25, 2014
P4, N=10, Recruiting, Sponsor: Arthritis Treatment Center, Maryland
N=10 --> 12 Not yet recruiting --> Recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: onset (clinicaltrials.gov) - Feb 25, 2014
P3, N=36, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Cimzia (certolizumab pegol) / Astellas, UCB
Biomarker, Trial completion, IO biomarker, Immunomodulating, Biopsy: Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia) (clinicaltrials.gov) - Feb 25, 2014
P3, N=12, Completed, Sponsor: Nathan Wei, MD, FACP, FACR:
Recruiting --> Active, not recruiting Recruiting --> Completed
- | prednisone delayed-release tablet / Generic mfg.
New P4 trial: Efficacy of Lodotra (clinicaltrials.gov) - Feb 24, 2014
P4, N=137, Recruiting, Sponsor: Mundipharma Korea Ltd
- ||| Biomarker, Enrollment open: A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers (clinicaltrials.gov) - Feb 24, 2014
P0, N=80, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Active, not recruiting --> Recruiting
- |||||| atacicept (VT-001) / Vera Therap
New P2b trial: Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II) (clinicaltrials.gov) - Feb 23, 2014
P2b, N=213, Not yet recruiting, Sponsor: EMD Serono
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS (clinicaltrials.gov) - Feb 23, 2014
P4, N=145, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting N=191 --> 145
- Enrollment open: EDIA: Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity (clinicaltrials.gov) - Feb 23, 2014
P1, N=120, Recruiting, Sponsor: Helsinki University
N=191 --> 145 Not yet recruiting --> Recruiting
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With Tocilizumab (RoActemra/Actemra) (clinicaltrials.gov) - Feb 23, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Rituxan (rituximab) / Roche
Enrollment closed: An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy (clinicaltrials.gov) - Feb 23, 2014
P=N/A, N=89, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| tgAAC94 gene therapy / Armata, Amgen
Trial completion: Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=120, Completed, Sponsor: Targeted Genetics Corporation
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Orencia (abatacept) / BMS
Trial completion: Remission and Joint Damage Progression in Early Rheumatoid Arthritis (clinicaltrials.gov) - Feb 22, 2014
P3, N=1052, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Health Behavior Change in Chronic Disease Management (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=20, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (clinicaltrials.gov) - Feb 22, 2014
P2, N=67, Completed, Sponsor: Biogen Idec
Not yet recruiting --> Completed No longer recruiting --> Completed
- |||| Trial completion: Study Evaluating TMI-005 in Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 22, 2014
P2, N=390, Completed, Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
No longer recruiting --> Completed No longer recruiting --> Completed
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Rituximab to Treat Stiff Person Syndrome (clinicaltrials.gov) - Feb 22, 2014
P2, N=24, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Cognitive-Behavioral Therapy and Tai Chi Chih for Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=106, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Recruiting --> Completed
- |||| Benlysta (belimumab) / GSK
Trial completion: A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Feb 22, 2014
P2, N=283, Completed, Sponsor: Human Genome Sciences Inc.
Recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Relaxation Response Training for the Treatment of Rheumatoid Arthritis (clinicaltrials.gov) - Feb 22, 2014
P4, N=168, Completed, Sponsor: Brigham and Women's Hospital
No longer recruiting --> Completed No longer recruiting --> Completed
- | pravastatin / Generic mfg.
Trial completion: Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE) (clinicaltrials.gov) - Feb 22, 2014
P2, N=150, Completed, Sponsor: Brigham and Women's Hospital
No longer recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Orencia (abatacept) / BMS
Trial completion, Combination therapy: A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate (clinicaltrials.gov) - Feb 22, 2014
P3, N=1250, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA) (clinicaltrials.gov) - Feb 22, 2014
P3, N=171, Completed, Sponsor: Abbott
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| tacrolimus intravenous / Generic mfg.
Trial completion: Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis (clinicaltrials.gov) - Feb 22, 2014
P3, N=210, Completed, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||||||| Tysabri (natalizumab) / Biogen, Royalty, Avonex (recombinant IFN-β-1a) / Biogen
Trial completion, Combination therapy: Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis (clinicaltrials.gov) - Feb 22, 2014
P3, N=1200, Completed, Sponsor: Biogen Idec
No longer recruiting --> Completed No longer recruiting --> Completed
- | Clinical: Efficacy of Diazoxide in Type 1 Diabetes (clinicaltrials.gov) - Feb 22, 2014
P4, N=40, Completed, Sponsor: Grill, Valdemar, M.D.
No longer recruiting --> Completed Active, not recruiting --> Completed